Grants Funded
ASPS/PSF leadership is committed to continuing to provide high levels of investigator-initiated research support to ensure that plastic surgeons have the needed research resources to be pioneers and innovators in advancing the practice of medicine.
Research Abstracts
Search The PSF database to have easy access to full-text grant abstracts from past PSF-funded research projects 2003 to present. All abstracts are the work of the Principal Investigators and were retrieved from their PSF grant applications. Several different filters may be applied to locate abstracts specific to a particular focus area or PSF funding mechanism.
HO-1 Gene Therapy for Pressure Ulcer Prophylaxis
Principal Investigator
Kevin Cross MD
Kevin Cross MD
Year
2007
2007
Institution
Weill Cornell Medical College
Weill Cornell Medical College
Funding Mechanism
Basic Research Grant
Basic Research Grant
Focus Area
Wounds / Scar
Wounds / Scar
Abstract
Pressure ulcers CPU) are a devastating and common comorbidity for all immobilized patients. PU are complicated by pain, infection, and increased hospital stay. The wounds represent a significant health care burden. In 2003, the average hospital acquired PU prevalence was 9.2% in the in-patient health care setting with 2.5 million PU treated each year. The cost for treating one full thickness PU is estimated to be $70,000 with total US expenditures equaling approximately $11 billion annually. Thus, there is great need for prophylaxis against PU formation. The primary aim of this study is to investigate the use of hypoxically driven heme oxygenase-1 (HO-l) gene therapy to prevent PU formation.
Pressure ulcers CPU) are a devastating and common comorbidity for all immobilized patients. PU are complicated by pain, infection, and increased hospital stay. The wounds represent a significant health care burden. In 2003, the average hospital acquired PU prevalence was 9.2% in the in-patient health care setting with 2.5 million PU treated each year. The cost for treating one full thickness PU is estimated to be $70,000 with total US expenditures equaling approximately $11 billion annually. Thus, there is great need for prophylaxis against PU formation. The primary aim of this study is to investigate the use of hypoxically driven heme oxygenase-1 (HO-l) gene therapy to prevent PU formation.